Recommendations for epidemiological studies on COPD

European Respiratory Journal

Volumn 38, Issue 6, 2011, Pages 1261-1277

  Bakke, P S ^a   Ronmark E ^b,c   Eagan, T ^a   Pistelli, F ^d   Annesi Maesano, I ^e   Maly, M ^f   Meren, M ^g   Vermeire, P ^h   Vestbo, J ^i,j   Viegi, G ^k,l   Zielinski, J ^m   Lundback B ^b,n  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b Central Hospital of Norrbotten   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e INSERM   (France)

^f NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^g Regionaalhaigla ^*  (Estonia)

^h UNIVERSITY OF ANTWERP   (Belgium)

ⁱ HVIDOVRE HOSPITAL   (Denmark)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k CNR   (Italy)

^l Clinical Physiology   (Italy)

^m NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

ⁿ UNIVERSITY OF GOTHENBURG   (Sweden)

more..

Author keywords

Biomarkers; Chronic obstructive pulmonary disease; Epidemiology; Lung function; Phenotypes; Questionnaires

Indexed keywords

IPRATROPIUM BROMIDE; SALBUTAMOL;

AIRFLOW; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CRITERION VARIABLE; DIET; DISEASE SEVERITY; EMPHYSEMA; FAMILY HISTORY; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; GENETIC SUSCEPTIBILITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INDOOR AIR POLLUTION; INSPIRATORY CAPACITY; LUNG FUNCTION; NORTH AMERICA; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SMOKING; SOCIAL STATUS; SOCIOECONOMICS; SPIROMETRY; THORAX RADIOGRAPHY; TOTAL LUNG CAPACITY; VITAL CAPACITY; WESTERN EUROPE;

BIOLOGICAL MARKERS; EPIDEMIOLOGIC STUDIES; EUROPE; FEMALE; HUMANS; MALE; NORTH AMERICA; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN; RISK FACTORS; SMOKING;

EID: 82555185065     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00193809     Document Type: Review

References (152)

1. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006;27: 188-207. (Pubitemid 43092683)
2. Murray CJ, Lopez AD Alternative projections of mortality, disability by cause 1990-2020. Global Burden of Disease Study. Lancet 1997; 349: 1498-1504. (Pubitemid 27216360)
3. Anto JM, Vermeire P, Vestbo J, et al. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-994. (Pubitemid 32600349)
4. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750. (Pubitemid 47321907)
5. Vestbo J, Langer SW, Iversen ET, et al. [Long-term prognosis of pulmonary sarcoidosis. 2. Cardiac sarcoidosis and other extrapulmonary manifestations]. Ugeskr Laeger 1995; 157: 2848-2850.
6. Johannessen A, Omenaas E, Bakke P, et al. Incidence of GOLD-defined chronic obstructive pulmonary disease in a general adult population. Int J Tuberc Lung Dis 2005; 9: 926-932. (Pubitemid 41139654)
7. Lindberg A, Eriksson B, Larsson LG, et al. Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest 2006; 129: 879-885.
8. Lokke A, Lange P, Scharling H, et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935-939. (Pubitemid 44787161)
9. 1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax 2008; 63: 1040-1045.
10. Gulsvik A. Major respiratory diseases. In: Loddenkemper R, Gibson GJ, Sibille Y, eds. European Lung White Book. Brussels, European Respiratory Society, 2003; pp. 34-43.
11. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report. National Institute of Health, 27012004.
12. Celli BR, MacNee W ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946. (Pubitemid 38807371)
13. American Thoracic Society. Guidelines as to what constitutes an adverse respiratory health effect, with special reference to epidemiologic studies on air pollution. Am Rev Respir Dis 1985; 131: 666-688.
14. Lebowitz MD, Knudson RJ, Burrows B. Tucson epidemiologic study of obstructive lung diseases. I: Methodology and prevalence of disease. Am J Epidemiol 1975; 102: 137-152.
15. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline, chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-1535. (Pubitemid 26141336)
16. Hospers JJ, Rijcken B, Schouten JP, et al. Eosinophilia and positive skin tests predict cardiovascular mortality in a general population sample followed for 30 years. Am J Epidemiol 1999; 150: 482-491. (Pubitemid 29407232)
17. Carrozzi L, Giuliano G, Viegi G, et al. The Po River Delta epidemiological study of obstructive lung disease: sampling methods, environmental and population characteristics. Eur J Epidemiol 1990; 6: 191-200. (Pubitemid 20352892)
18. Lundback B, Stjernberg N, Nystrom L, et al. Epidemiology of respiratory symptoms, lung function and important determinants. Report from the Obstructive Lung Disease in Northern Sweden Project. Tuber Lung Dis 1994; 75: 116-126. (Pubitemid 24157898)
19. Heederik D, Kromhout H, Burema J, et al. Occupational exposure and 25-year incidence rate of non-specific lung disease: the Zutphen Study. Int J Epidemiol 1990; 19: 945-952.
20. Bakke P, Eide GE, Hanoa R, et al. Occupational dust or gas exposure and prevalences of respiratory symptoms and asthma in a general population. Eur Respir J 1991; 4: 273-278.
21. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968. (Pubitemid 41632054)
22. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management and prevention of COPD. www.goldcopd.org/guidelines- global-strategy-for-diagnosis-management.html Date last updated: December 2010.
23. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52: S1-28.
24. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of lung function testing: the authors' replies to readers' comments. Eur Respir J 2010; 36: 1496-1498.
25. Hardie JA, Buist AS, Vollmer WM, et al. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20: 1117-1122. (Pubitemid 35331867)
26. 1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008; 63: 1046-1051.
27. Kohler D, Fischer J, Raschke F, et al. Usefulness of GOLD classification of COPD severity. Thorax 2003; 58: 825. (Pubitemid 37094065)
28. Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 627-643. (Pubitemid 43372539)
29. Pellegrino R, Brusasco V, Viegi G, et al. Definition of COPD: based on evidence or opinion? Eur Respir J 2008; 31: 681-682.
30. Mannino DM. Defining chronic obstructive pulmonary disease... and the elephant in the room. Eur Respir J 2007; 30: 189-190. (Pubitemid 47194169)
31. Miller MR, Pedersen OF, Lange P, et al. Improved survival prediction from lung function data in a large population sample. Respir Med 2009; 103: 442-448.
32. de Marco R. What evidence could validate the definition of COPD? Thorax 2008; 63: 756-757.
33. Vollmer WM, Gislason T, Burney P, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD Study. Eur Respir J 2009; 34: 588-597.
34. Johannessen A, Omenaas ER, Bakke PS, et al. Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax 2005; 60: 842-847. (Pubitemid 41475212)
35. Johannessen A, Lehmann S, Omenaas ER, et al. Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med 2006; 173: 1316-1325. (Pubitemid 43900705)
36. Schermer TR, Smeele IJ, Thoonen BP, et al. Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J 2008; 32: 945-952.
37. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338. (Pubitemid 41079078)
38. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J 2005; 26: 153-161. (Pubitemid 40945944)
39. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.
40. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202-1218.
41. Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS workshop on lung volume measurements. Official statement of the European Respiratory Society. Eur Respir J 1995; 8: 492-506.
42. Johannessen A, Omenaas ER, Eide GE, et al. Feasible and simple exclusion criteria for pulmonary reference populations. Thorax 2007; 62: 792-798.
43. Pistelli F, Bottai M, Carrozzi L, et al. Reference equations for spirometry from a general population sample in central Italy. Respir Med 2007; 101: 814-825.
44. O'Donnell DE, Laveneziana P. Dyspnea, activity limitation in COPD. mechanical factors. COPD 2007; 4: 225-236. (Pubitemid 47345897)
45. O'Donnell DE. [Dynamic lung hyperinflation and its clinical implication in COPD]. Rev Mal Respir 2008; 25: 1305-1318.
46. Viegi G, Sherrill DL, Carrozzi L, et al. An 8-year follow-up of carbon monoxide diffusing capacity in a general population sample of northern Italy. Chest 2001; 120: 74-80. (Pubitemid 32744860)
47. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26: 511-522. (Pubitemid 41264217)
48. de Marco R, Accordini S, Cerveri I, et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007; 175: 32-39. (Pubitemid 46105306)
49. Bridevaux PO, Gerbase MW, Probst-Hensch NM, et al. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008; 63: 768-774.
50. Liard R, Neukirch F. Questionnaires: a major instrument for respiratory epidemiology. In: Annesi-Maesano I, Gulsvik A, Viegi G. Respiratory Epidemiology in Europe. Eur Respir Mon 2000; 5: 154-166.
51. Brogger JC, Bakke PS, Gulsvik A. Comparison of respiratory symptoms questionnaires. Int J Tuberc Lung Dis 2000; 4: 83-90. (Pubitemid 30059289)
52. Giuntini C, Viegi G, eds. Epidemiologic determinats of COPD in some European countries. Eur Respir Rev 2001; 11: 47-143.
53. Pistelli F, Viegi G, Carrozzi L, et al. Appendix 3: Compendium of respiratory standard questionnaires for adults (CORSQ). Eur Respir Rev 2001; 11: 118-143. (Pubitemid 32906465)
54. Pistelli F, Viegi G, Carrozzi L, et al. Usefulness of a compendium of respiratory standard questionnaires for adults (CORSQ). Eur Respir Rev 2001; 11: 98-102. (Pubitemid 32906462)
55. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints. preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95. (Pubitemid 32225406)
56. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653. (Pubitemid 38787999)
57. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 6-14. (Pubitemid 43955238)
58. Snell N, Newbold P. The clinical utility of biomarkers in asthma and COPD. Curr Opin Pharmacol 2008; 8: 222-235.
59. Horvath I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005; 26: 523-548. (Pubitemid 41264218)
60. Liu J, Conrad DH, Chow S, et al. Collection devices influence the constituents of exhaled breath condensate. Eur Respir J 2007; 30: 807-808. (Pubitemid 351194845)
61. Rosias PP, Robroeks CM, Niemarkt HJ, et al. Breath condenser coatings affect measurement of biomarkers in exhaled breath condensate. Eur Respir J 2006; 28: 1036-1041. (Pubitemid 46331976)
62. Borrill ZL, Roy K, Singh D. Exhaled breath condensate biomarkers in COPD. Eur Respir J 2008; 32: 472-486.
63. Pin I, Gibson PG, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: 25-29.
64. Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009; 34: 95-102.
65. Eagan TML, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J 2010; 35: 540-548.
66. Sin DD, Man SF. Biomarkers in COPD: are we there yet? Chest 2008; 133: 1296-1298. (Pubitemid 351892982)
67. Celli BR Roger S Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. Proc Am Thorac Soc 2006; 3: 461-465. (Pubitemid 44285511)
68. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
69. Jones PW. Testing health status ("quality of life") questionnaires for asthma and COPD. Eur Respir J 1998; 11: 5-6. (Pubitemid 28081787)
70. Gelb AF, Hogg JC, Muller NL, et al. Contribution of emphysema and small airways in COPD. Chest 1996; 109: 353-359. (Pubitemid 26058588)
71. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnoea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012. (Pubitemid 38269277)
72. Friedlander AL, Lynch D, Dyar LA, et al. Phenotypes of chronic obstructive pulmonary disease. COPD 2007; 4: 355-384. (Pubitemid 350135871)
73. Pons AR, Noguera A, Blanquer D, et al. Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD. Eur Respir J 2005; 25: 647-652. (Pubitemid 40528757)
74. de Jong PA, Muller NL, Pare PD, et al. Computed tomographic imaging of the airways: relationship to structure and function. Eur Respir J 2005; 26: 140-152. (Pubitemid 40945943)
75. Vestbo J. Clinical assessment, staging, and epidemiology of chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 2006; 3: 252-256. (Pubitemid 43668190)
76. Pistolesi M, Camiciottoli G, Paoletti M, et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med 2008; 102: 367-376.
77. Sherrill DL, Lebowitz MD, Knudson RJ, et al. Longitudinal methods for describing the relationship between pulmonary function, respiratory symptoms and smoking in elderly subjects: the Tucson Study. Eur Respir J 1993; 6: 342-348. (Pubitemid 23114878)
78. Schlesselman JJ. Planning a longitudinal study: II. Frequency of measurement and study duration. J Chron Dis 1973; 26: 561-570.
79. Dales RE, Hanley JA, Ernst P, et al. Computer modelling of measurement error in longitudinal lung function data. J Chronic Dis 1987; 40: 769-773. (Pubitemid 17113510)
80. Wise RA. The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. Am J Med 2006; 119: 4-11. (Pubitemid 44402279)
81. 1 by age and smoking status: facts, figures, and fallacies. Thorax 1997; 52: 820-827.
82. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax 2006; 61: 472-477. (Pubitemid 43901515)
83. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
84. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204. (Pubitemid 17009877)
85. Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179: 369-374.
86. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 867-874. (Pubitemid 44564786)
87. Kim WD, Ling SH, Coxson HO, et al. The association between small airway obstruction and emphysema phenotypes in COPD. Chest 2007; 131: 1372-1378. (Pubitemid 46762341)
88. Dirksen A. Is CT a new research tool for COPD? Clin Respir J 2008; 2: 76-83.
89. Makita H, Nasuhara Y, Nagai K, et al. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 2007; 62: 932-937.
90. Coxson HO. Quantitative computed tomography assessment of airway wall dimensions: current status and potential applications for phenotyping chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 940-945.
91. Grydeland TB, Dirksen A, Coxson HO, et al. Quantitative CT: emphysema and airway wall thickness by gender, age and smoking. Eur Respir J 2009; 34: 858-865.
92. Patel BD, Coxson HO, Pillai SG, et al. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178: 500-505.
93. Williamson JP, James AL, Phillips MJ, et al. Quantifying tracheobronchial tree dimensions: methods, limitations and emerging techniques. Eur Respir J 2009; 34: 42-55.
94. Coxson HO, Mayo J, Lam S, et al. New and current clinical imaging techniques to study chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 588-597.
95. Gosker HR, Zeegers MP, Wouters EF, et al. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax 2007; 62: 944-949. (Pubitemid 350084491)
96. Schols AM, Broekhuizen R, Weling-Scheepers CA, et al. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005; 82: 53-59. (Pubitemid 41716377)
97. Schols AM. Nutritional rehabilitation: from pulmonary cachexia to sarcoPD. Eur Respir J 2009; 33: 949-950.
98. Patrick DL, Cheadle A, Thompson DC, et al. The validity of self-reported smoking: a review and meta-analysis. Am J Public Health 1994; 84: 1086-1093. (Pubitemid 24242478)
99. Slama K. Active smoking. In: Annesi-Maesano I, Gulsvik A, Viegi G, eds. Respiratory Epidemiology in Europe. Eur Respir Mon 2000; 5: 305-321.
100. Murray RP, Connett JE, Lauger GG, et al. Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group. Am J Public Health 1993; 83: 1251-1257. (Pubitemid 23262028)
101. Blanc PD, Eisner MD, Balmes JR, et al. Exposure to vapors, gas, dust, or fumes: assessment by a single survey item compared to a detailed exposure battery and a job exposure matrix. Am J Ind Med 2005; 48: 110-117. (Pubitemid 41134213)
102. Balmes J, Becklake M, Blanc P, et al. American Thoracic Society statement: Occupational contribution to the burden of airway disease. Am J Respir Crit Care Med 2003; 167: 787-797.
103. Bakke PS, Hanoa R, Gulsvik A. Relation of occupational exposure to respiratory symptoms and asthma in a general population sample: self-reported versus interview-based exposure data. Am J Epidemiol 2001; 154: 477-483. (Pubitemid 32845486)
104. Mannetje A, Kromhout H. The use of occupation and industry classifications in general population studies. Int J Epidemiol 2003; 32: 419-428.
105. Matheson MC, Benke G, Raven J, et al. Biological dust exposure in the workplace is a risk factor for chronic obstructive pulmonary disease. Thorax 2005; 60: 645-651. (Pubitemid 41129062)
106. Bakke P, Baste V, Hanoa R, et al. Occupational airborne exposure of the general population of a Norwegian county. Scand J Work Environ Health 1992; 18: 44-51.
107. Le Moual N, Bakke P, Orlowski E, et al. Performance of population specific job exposure matrices (JEMs): European collaborative analyses on occupational risk factors for chronic obstructive pulmonary disease with job exposure matrices (ECOJEM). Occup Environ Med 2000; 57: 126-132. (Pubitemid 30265457)
108. Bakke PS, Hanoa R, Gulsvik A. Relation of occupational exposure to respiratory symptoms and asthma in a general population sample: self-reported versus interview-based exposure data. Am J Epidemiol 2001; 154: 477-483. (Pubitemid 32845486)
109. Skorge TD, Eagan TM, Eide GE, et al. Indoor exposures and respiratory symptoms in a Norwegian community sample. Thorax 2005; 60: 937-942. (Pubitemid 41598209)
110. Gunnbjornsdottir MI, Franklin KA, Norback D, et al. Prevalence and incidence of respiratory symptoms in relation to indoor dampness: the RHINE study. Thorax 2006; 61: 221-225.
111. Aamodt AH, Bakke P, Gulsvik A. Reproducibility of indoor environment characteristics obtained in a walk through questionnaire. A pilot study. Indoor Air 1999; 9: 26-32. (Pubitemid 129738227)
112. Brunekreef B. Indoor environment. In: Annesi-Maesano I, Gulsvik A, Viegi G, eds. Respiratory Epidemiology in Europe. Eur Respir Mon 2000; 5: 384-399.
113. Dales RE, Miller D, McMullen E. Indoor air quality and health: validity and determinants of reported home dampness and moulds. Int J Epidemiol 1997; 26: 120-125. (Pubitemid 27129576)
114. Larsson ML, Loit HM, Meren M, et al. Passive smoking and respiratory symptoms in the FinEsS Study. Eur Respir J 2003; 21: 672-676. (Pubitemid 36432524)
115. Skorge TD, Eagan TM, Eide GE, et al. The adult incidence of asthma and respiratory symptoms by passive smoking in uterus or in childhood. Am J Respir Crit Care Med 2005; 172: 61-66. (Pubitemid 40923315)
116. Ackermann-Liebrich U. Outdoor air pollution. In: Annesi-Maesano I, Gulsvik A, Viegi G, eds. Respiratory Epidemiology in Europe. Eur Respir Mon 2000; 5: 400-411.
117. Valero N, Aguilera I, Llop S, et al. Concentrations and determinants of outdoor, indoor and personal nitrogen dioxide in pregnant females from two Spanish birth cohorts. Environ Int 2009; 35: 1196-1201.
118. Viegi G, Maio S, Pistelli F, et al. Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution. Respirology 2006; 11: 523-532. (Pubitemid 44186256)
119. Sunyer J, Jarvis D, Gotschi T, et al. Chronic bronchitis and urban air pollution in an international study. Occup Environ Med 2006; 63: 836-843. (Pubitemid 46024934)
120. Bakke PS, Hanoa R, Gulsvik A. Educational level and obstructive lung disease given smoking habits and occupational airborne exposure: a Norwegian community study. Am J Epidemiol 1995; 141: 1080-1088.
121. Prescott E, Godtfredsen N, Vestbo J, et al. Social position and mortality from respiratory diseases in males and females. Eur Respir J 2003; 21: 821-826. (Pubitemid 36592292)
122. Liberatos P, Link BG, Kelsey JL. The measurement of social class in epidemiology. Epidemiol Rev 1988; 10: 87-121. (Pubitemid 18262842)
123. Seaton A. Diet. In: Annesi-Maesano I, Gulsvik A, Viegi G, eds. Respiratory Epidemiology in Europe. Eur Respir Mon 2000; 5: 412-428.
124. Farchi S, Forastiere F, Pistelli R, et al. Exposure to environmental tobacco smoke is associated with lower plasma beta-carotene levels among nonsmoking females married to a smoker. Cancer Epidemiol Biomarkers Prev 2001; 10: 907-909. (Pubitemid 32738606)
125. Maclay JD, McAllister DA, Macnee W. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology 2007; 12: 634-641. (Pubitemid 47414891)
126. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 1286-1293. (Pubitemid 39657192)
127. Norwood RJ. A review of etiologies of depression in COPD. Int J Chron Obstruct Pulmon Dis 2007; 2: 485-491.
128. Quint JK, Baghai-Ravary R, Donaldson GC, et al. Relationship between depression and exacerbations in COPD. Eur Respir J 2008; 32: 53-60.
129. Cote C, Zilberberg MD, Mody SH, et al. haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007; 29: 923-929. (Pubitemid 46711896)
130. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257. (Pubitemid 44883863)
131. de Groot V, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003; 56: 221-229. (Pubitemid 36513483)
132. Vermeeren MA, Creutzberg EC, Schols AM, et al. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med 2006; 100: 1349-1355. (Pubitemid 43942332)
133. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97: 115-122. (Pubitemid 36284990)
134. Kotaniemi JT, Latvala J, Lundback B, et al. Does living in a cold climate or recreational skiing increase the risk for obstructive respiratory diseases or symptoms? Int J Circumpolar Health 2003; 62: 142-157.
135. Montnemery P, Lanke J, Lindholm LH, et al. Familial related risk-factors in the development of chronic bronchitis/emphysema as compared to asthma assessed in a postal survey. Eur J Epidemiol 2000; 16: 1003-1007. (Pubitemid 34815001)
136. Shieh G. On power and sample size calculations for likelihood ratio tests in generalized linear models. Biometrics 2000; 56: 1192-1196.
137. Magder LS, Hughes JP. Logistic regression when the outcome is measured with uncertainty. Am J Epidemiol 1997; 146: 195-203.
138. Ronmark E, Lundqvist A, Lundback B, et al. Non-responders to a postal questionnaire on respiratory symptoms and diseases. Eur J Epidemiol 1999; 15: 293-299. (Pubitemid 29262362)
139. Kotaniemi JT, Hassi J, Kataja M, et al. Does non-responder bias have a significant effect on the results in a postal questionnaire study? Eur J Epidemiol 2001; 17: 809-817. (Pubitemid 34602322)
140. Eagan TM, Eide GE, Gulsvik A, et al. Nonresponse in a community cohort study: predictors and consequences for exposure-disease associations. J Clin Epidemiol 2002; 55: 775-781.
141. Hardie JA, Bakke PS, Morkve O. Non-response bias in a postal questionnaire survey on respiratory health in the old and very old. Scand J Public Health 2003; 31: 411-417.
142. Rönmark EP, Ekerljung L, Lötvall J, et al. Large scale questionnaire survey on respiratory health in Sweden: effects of late- and non-response. Respir Med 2009; 103: 1807-1815.
143. Perneger TV, Etter JF, Rougemont A. Randomized trial of use of a monetary incentive and a reminder card to increase the response rate to a mailed health survey. Am J Epidemiol 1993; 138: 714-722. (Pubitemid 23339014)
144. Edwards PJ, Roberts I, Clarke MJ, et al. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev 2009; 8: MR000008.
145. Hardie JA, Vollmer WM, Buist AS, et al. Respiratory symptoms and obstructive pulmonary disease in a population aged over 70 years. Respir Med 2005; 99: 186-195. (Pubitemid 40104273)
146. Brogger J, Nystad W, Cappelen I, et al. No increase in response rate by adding a web response option to a postal population survey: a randomized trial. J Med Internet Res 2007; 9: e40.
147. Armstrong BK, White E, Saracci R. Principles of exposure measurement in epidemiology. Oxford, Oxford University Press, 1992.
148. Viegi G, Simoni M, Pistelli F, et al. Inter-laboratory comparison of flow-volume curve measurements as quality control procedure in the framework of an international epidemiological study (PEACE project). Respir Med 2000; 94: 194-203. (Pubitemid 30198068)
149. Enright PL, Johnson LR, Connett JE, et al. Spirometry in the Lung Health Study. 1. Methods and quality control. Am Rev Respir Dis 1991; 143: 1215-1223.
150. 1 due to technician, team, device and subject in an eight centre study: three quality control studies in SAPALDIA. Swiss Study on Air Pollution and Lung Disease in Adults. Eur Respir J 1995; 8: 371-376.
151. Bellia V, Pistelli R, Catalano F, et al. Quality control of spirometry in the elderly. The SA.R.A. study. SAlute Respiration nell'Anziano = Respiratory Health in the Elderly. Am J Respir Crit Care Med 2000; 161: 1094-1100.
152. Buist AS, Vollmer WM, Sullivan SD, et al. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD 2005; 2: 277-283. (Pubitemid 40993302)